(SLAB) Silicon Laboratories - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US8269191024
Stock: Semiconductors, Microcontrollers, Wireless, Sensors
Total Rating 65
Risk 83
Buy Signal 0.03
| Risk 5d forecast | |
|---|---|
| Volatility | 48.5% |
| Relative Tail Risk | -10.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.86 |
| Alpha | 23.44 |
| Character TTM | |
|---|---|
| Beta | 1.668 |
| Beta Downside | 2.928 |
| Drawdowns 3y | |
|---|---|
| Max DD | 51.13% |
| CAGR/Max DD | 0.10 |
EPS (Earnings per Share)
Revenue
Description: SLAB Silicon Laboratories March 05, 2026
Silicon Laboratories Inc. (SLAB) is a fabless semiconductor company. This business model relies on outsourcing semiconductor fabrication, allowing focus on design and sales. They develop mixed-signal analog intensive products for industrial and commercial Internet of Things (IoT) applications.
Their products are integrated into diverse electronic devices, spanning smart home systems, industrial automation, and connected health applications. The IoT sector is characterized by a rapidly expanding ecosystem of interconnected devices. SLAB distributes its products through a direct sales force and a network of representatives and distributors.
To deepen your understanding of SLABs market position and financial health, explore further research on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: -64.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 7.28 > 1.0 |
| NWC/Revenue: 67.57% < 20% (prev 86.27%; Δ -18.70% < -1%) |
| CFO/TA 0.08 > 3% & CFO 95.7m > Net Income -64.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.69 > 1.5 & < 3 |
| Outstanding Shares: last quarter (32.9m) vs 12m ago 1.54% < -2% |
| Gross Margin: 58.23% > 18% (prev 0.53%; Δ 5770 % > 0.5%) |
| Asset Turnover: 62.98% > 50% (prev 47.80%; Δ 15.19% > 0%) |
| Interest Coverage Ratio: -58.63 > 6 (EBITDA TTM -19.1m / Interest Expense TTM 975.0k) |
Altman Z'' 10.00
| A: 0.42 (Total Current Assets 674.0m - Total Current Liabilities 143.8m) / Total Assets 1.27b |
| B: 0.74 (Retained Earnings 936.8m / Total Assets 1.27b) |
| C: -0.05 (EBIT TTM -57.2m / Avg Total Assets 1.25b) |
| D: 5.36 (Book Value of Equity 937.0m / Total Liabilities 174.9m) |
| Altman-Z'' Score: 10.46 = AAA |
Beneish M -3.13
| DSRI: 0.88 (Receivables 64.5m/54.5m, Revenue 784.8m/584.4m) |
| GMI: 0.92 (GM 58.23% / 53.42%) |
| AQI: 0.92 (AQ_t 0.37 / AQ_t-1 0.40) |
| SGI: 1.34 (Revenue 784.8m / 584.4m) |
| TATA: -0.13 (NI -64.9m - CFO 95.7m) / TA 1.27b) |
| Beneish M-Score: -3.13 (Cap -4..+1) = AA |
What is the price of SLAB shares?
As of March 05, 2026, the stock is trading at USD 203.58 with a total of 822,692 shares traded.
Over the past week, the price has changed by -0.28%, over one month by +0.08%, over three months by +46.73% and over the past year by +51.97%.
Over the past week, the price has changed by -0.28%, over one month by +0.08%, over three months by +46.73% and over the past year by +51.97%.
Is SLAB a buy, sell or hold?
Silicon Laboratories has received a consensus analysts rating of 3.73.
Therefor, it is recommend to hold SLAB.
- StrongBuy: 3
- Buy: 2
- Hold: 6
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SLAB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 222.9 | 9.5% |
| Analysts Target Price | 222.9 | 9.5% |
SLAB Fundamental Data Overview March 04, 2026
P/E Forward = 75.7576
P/S = 8.6051
P/B = 6.1704
P/EG = 3.0343
Revenue TTM = 784.8m USD
EBIT TTM = -57.2m USD
EBITDA TTM = -19.1m USD
Long Term Debt = 24.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = -364.2m USD (from netDebt column, last quarter)
Enterprise Value = 6.39b USD (6.75b + (null Debt) - CCE 364.2m)
Interest Coverage Ratio = -58.63 (Ebit TTM -57.2m / Interest Expense TTM 975.0k)
EV/FCF = 97.11x (Enterprise Value 6.39b / FCF TTM 65.8m)
FCF Yield = 1.03% (FCF TTM 65.8m / Enterprise Value 6.39b)
FCF Margin = 8.38% (FCF TTM 65.8m / Revenue TTM 784.8m)
Net Margin = -8.27% (Net Income TTM -64.9m / Revenue TTM 784.8m)
Gross Margin = 58.23% ((Revenue TTM 784.8m - Cost of Revenue TTM 327.8m) / Revenue TTM)
Gross Margin QoQ = 63.44% (prev 57.78%)
Tobins Q-Ratio = 5.03 (Enterprise Value 6.39b / Total Assets 1.27b)
Interest Expense / Debt = unknown (Interest Expense 214.0k / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = -45.2m (EBIT -57.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.69 (Total Current Assets 674.0m / Total Current Liabilities 143.8m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = 19.09 (negative EBITDA) (Net Debt -364.2m / EBITDA -19.1m)
Debt / FCF = -5.54 (Net Debt -364.2m / FCF TTM 65.8m)
Total Stockholder Equity = 1.07b (last 4 quarters mean from totalStockholderEquity)
RoA = -5.21% (Net Income -64.9m / Total Assets 1.27b)
RoE = -6.05% (Net Income TTM -64.9m / Total Stockholder Equity 1.07b)
RoCE = -5.21% (EBIT -57.2m / Capital Employed (Equity 1.07b + L.T.Debt 24.0m))
RoIC = -4.21% (negative operating profit) (NOPAT -45.2m / Invested Capital 1.07b)
WACC = 12.06% (E(6.75b)/V(6.75b) * Re(12.06%) + (debt-free company))
Discount Rate = 12.06% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.67%
[DCF] Terminal Value 54.40% ; FCFF base≈65.8m ; Y1≈43.2m ; Y5≈19.7m
[DCF] Fair Price = 18.04 (EV 230.3m - Net Debt -364.2m = Equity 594.5m / Shares 33.0m; r=12.06% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: -51.69 | EPS CAGR: -15.43% | SUE: 0.13 | # QB: 0
Revenue Correlation: -35.41 | Revenue CAGR: -3.05% | SUE: 0.43 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.66 | Chg7d=+0.004 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=10
EPS current Year (2026-12-31): EPS=2.71 | Chg7d=+0.001 | Chg30d=+0.016 | Revisions Net=+1 | Growth EPS=+194.2% | Growth Revenue=+18.1%
EPS next Year (2027-12-31): EPS=4.14 | Chg7d=+0.112 | Chg30d=+0.114 | Revisions Net=+2 | Growth EPS=+53.1% | Growth Revenue=+16.3%
[Analyst] Revisions Ratio: +0.00 (3 Up / 3 Down within 30d for Next Quarter)
P/S = 8.6051
P/B = 6.1704
P/EG = 3.0343
Revenue TTM = 784.8m USD
EBIT TTM = -57.2m USD
EBITDA TTM = -19.1m USD
Long Term Debt = 24.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = -364.2m USD (from netDebt column, last quarter)
Enterprise Value = 6.39b USD (6.75b + (null Debt) - CCE 364.2m)
Interest Coverage Ratio = -58.63 (Ebit TTM -57.2m / Interest Expense TTM 975.0k)
EV/FCF = 97.11x (Enterprise Value 6.39b / FCF TTM 65.8m)
FCF Yield = 1.03% (FCF TTM 65.8m / Enterprise Value 6.39b)
FCF Margin = 8.38% (FCF TTM 65.8m / Revenue TTM 784.8m)
Net Margin = -8.27% (Net Income TTM -64.9m / Revenue TTM 784.8m)
Gross Margin = 58.23% ((Revenue TTM 784.8m - Cost of Revenue TTM 327.8m) / Revenue TTM)
Gross Margin QoQ = 63.44% (prev 57.78%)
Tobins Q-Ratio = 5.03 (Enterprise Value 6.39b / Total Assets 1.27b)
Interest Expense / Debt = unknown (Interest Expense 214.0k / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = -45.2m (EBIT -57.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.69 (Total Current Assets 674.0m / Total Current Liabilities 143.8m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = 19.09 (negative EBITDA) (Net Debt -364.2m / EBITDA -19.1m)
Debt / FCF = -5.54 (Net Debt -364.2m / FCF TTM 65.8m)
Total Stockholder Equity = 1.07b (last 4 quarters mean from totalStockholderEquity)
RoA = -5.21% (Net Income -64.9m / Total Assets 1.27b)
RoE = -6.05% (Net Income TTM -64.9m / Total Stockholder Equity 1.07b)
RoCE = -5.21% (EBIT -57.2m / Capital Employed (Equity 1.07b + L.T.Debt 24.0m))
RoIC = -4.21% (negative operating profit) (NOPAT -45.2m / Invested Capital 1.07b)
WACC = 12.06% (E(6.75b)/V(6.75b) * Re(12.06%) + (debt-free company))
Discount Rate = 12.06% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.67%
[DCF] Terminal Value 54.40% ; FCFF base≈65.8m ; Y1≈43.2m ; Y5≈19.7m
[DCF] Fair Price = 18.04 (EV 230.3m - Net Debt -364.2m = Equity 594.5m / Shares 33.0m; r=12.06% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: -51.69 | EPS CAGR: -15.43% | SUE: 0.13 | # QB: 0
Revenue Correlation: -35.41 | Revenue CAGR: -3.05% | SUE: 0.43 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.66 | Chg7d=+0.004 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=10
EPS current Year (2026-12-31): EPS=2.71 | Chg7d=+0.001 | Chg30d=+0.016 | Revisions Net=+1 | Growth EPS=+194.2% | Growth Revenue=+18.1%
EPS next Year (2027-12-31): EPS=4.14 | Chg7d=+0.112 | Chg30d=+0.114 | Revisions Net=+2 | Growth EPS=+53.1% | Growth Revenue=+16.3%
[Analyst] Revisions Ratio: +0.00 (3 Up / 3 Down within 30d for Next Quarter)